Mads Engelmann

Mads Engelmann serves as the International Medical Vice President at Novo Nordisk A/S since April 2013, overseeing strategic, regulatory, and medical aspects of clinical research with a focus on cardiovascular expertise. Prior to this role, Mads held positions including Global Medical Director at Eli Lilly and Company, focusing on late-stage development and commercialization of key diabetes products, and Head of Medical Affairs at aCROnordic A/S. Mads has also served as Chief Medical Officer at AstraZeneca and Director of Medical Affairs at GlaxoSmithKline. Mads holds an MD, PhD from the University of Copenhagen, a BSc in Chemical Engineering, and has completed business education at Harvard Business School and London Business School.